Emergent Biosolutions Inc (EBS) : Eqis Capital Management reduced its stake in Emergent Biosolutions Inc by 14.13% during the most recent quarter end. The investment management company now holds a total of 51,760 shares of Emergent Biosolutions Inc which is valued at $1,668,225 after selling 8,518 shares in Emergent Biosolutions Inc , the firm said in a disclosure report filed with the SEC on Oct 4, 2016.Emergent Biosolutions Inc makes up approximately 0.10% of Eqis Capital Management’s portfolio.
Emergent Biosolutions Inc closed down -0.07 points or -0.22% at $31.55 with 5,92,460 shares getting traded on Tuesday. Post opening the session at $31.79, the shares hit an intraday low of $31.1 and an intraday high of $31.99 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Emergent Biosolutions Inc reported $-0.27 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.17. The company had revenue of $101.49 million for the quarter, compared to analysts expectations of $111.12 million. The company’s revenue was down -19.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.36 EPS.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.